Shanghai Juncell Therapeutics’ GC101 TIL Therapy Receives CDE Approval for Pivotal Phase II Trial
Shanghai Juncell Therapeutics has announced that the National Medical Products Administration’s Center for Drug Evaluation...
Drug
Novatim Immune Therapeutics’ Y-0301 Receives FDA Clearance for Clinical Trials
China-based cancer immunotherapy specialist Novatim Immune Therapeutics (Zhejiang) Co., Ltd. has announced receiving clinical clearance...
HighField Biopharmaceutical’s HF50 Receives Tacit Clinical Approval from NMPA for HER-2 Positive Tumors
Hangzhou-based HighField Biopharmaceutical, a specialist in immuno-oncology biotech focused on targeted lipid-based therapies, has revealed...
Shenyang Hongqi Pharma Secures NMPA Approval for Pretomanid in TB Treatment
The National Medical Products Administration (NMPA) of China has officially approved pretomanid, developed by Shenyang...
Jiangsu Hengrui’s SHR-A2102 Earns Breakthrough Therapy Designation for Urothelial Carcinoma
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received breakthrough therapy...
Roche’s Columvi Supplemental sBLA Accepted by FDA for Relapsed DLBCL Treatment
Swiss pharmaceutical giant Roche (SWX: ROG) has announced that the US Food and Drug Administration...
Teva Pharmaceutical to Divest Holdings in Teva Takeda Pharma to JKI
Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has announced its intention to sell all holdings...
Dewpoint Therapeutics Partners with Mitsubishi Tanabe Pharma to Develop ALS Treatment
US-based Dewpoint Therapeutics Inc. has entered into a strategic partnership with Japan-headquartered Mitsubishi Tanabe Pharma...
AstraZeneca’s Imfinzi Receives FDA Approval for Limited-Stage Small Cell Lung Cancer
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has reported receiving a new indication approval from...
Merck Initiates Phase III MOVE-NOW Study for Lagevrio COVID-19 Antiviral
US pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced the commencement of the...
CDE Approves RinuaGene’s mRNA-Based RG002 for Clinical Study in Cervical Dysplasia
China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has indicated...
Eli Lilly’s Zepbound Outperforms Wegovy in SURMOUNT-5 Weight Loss Study
US pharmaceutical major Eli Lilly & Co., (NYSE: LLY) has revealed a positive readout from...
Phanes Therapeutics’ PT217 Earns FDA Fast Track Designation for Neuroendocrine Prostate Cancer
Sino-US biotech company Phanes Therapeutics Inc. has announced that it has received another Fast Track...
CGeneTech’s Cetagliptin Receives NMPA Approval for Type 2 Diabetes Treatment in China
The National Medical Products Administration (NMPA) in China has indicated on its website that CGeneTech...
Eisai and Biogen’s Leqembi Approved in Mexico for Early Alzheimer’s Disease Treatment
Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have announced that their co-developed...
Shanghai Escugen Receives NMPA Approval for Second Phase III Trial of ESG401 in TNBC
Shanghai Escugen, a China-based biopharmaceutical company, has announced receiving the green light from the National...
Johnson & Johnson Submits sBLAs to FDA for Tremfya Indications in Pediatric Psoriasis and Arthritis
Global healthcare giant Johnson & Johnson (J&J; NYSE: JNJ) has announced the submission of two...
Merus N.V. Receives FDA Approval for Bizengri for NRG1+ Pancreatic and Lung Cancers
Holland-based Merus N.V. (NASDAQ: MRUS) has announced that it has received FDA approval for its...
Ipsen’s Bylvay Receives NMPA Clearance for Treating Itching in PFIC Patients in China
France-based Ipsen (EPA: IPN) has announced that it has received marketing clearance from the National...
Tasly Pharma Receives NMPA Approval for Generic Lioresal (Baclofen) Oral Solution
China-based Tasly Pharma Co., Ltd (SHA: 600535) has announced that it has received marketing approval...